Apply Now

Cocaine Use
Research Study

Researchers at the University of California, Los Angeles are evaluating a potential treatment to help people cut down or stop using cocaine. Join our study today!

See If I Qualify

Fast Facts

cocaine user

interested in reducing or stopping cocaine use

ages 18-65

compensation up to $1603

conducted in Los Angeles, CA

Study Background

Researchers at the University of California, Los Angeles (UCLA) are investigating whether a combined treatment of injectable medications can help reduce or stop cocaine use.

Findings from this clinical research study will determine the safety and efficacy of a combination of extended release Naltrexone (Vivitrol) and extended-release Buprenophrine (Sublocade).

Participants will be asked to attend study visits twice weekly for sample collection, assessments, and medical management. Injections will be administered during the 8 week medication phase. Then participants will complete a follow-up phase weeks 9-12.

Further research today and join our compensated study!

See If I Qualify

Additional Information

The purpose of this study is to see if a combined treatment of injectable extended-release naltrexone (XR-NTX; Vivitrol®) and injectable extended-release Buprenorphine (XR-BUP; Sublocade®) are safe and effective for helping people cut down or stop using cocaine.

You may qualify for this study if you meet the following criteria.

Key Criteria:

  • Ages 18-65
  • Cocaine user
  • Interested in reducing or stopping cocaine use

Once enrolled, this study involves:

  • Attending study visits twice weekly
    • Includes urine samples, assessments, and medical management
  • Receiving injections on the randomization day and at week 3 and 6
  • Receiving another injection 4-6 days after randomization and at week 4
  • Completing a follow-up phase during weeks 9-12

Compensation is provided up to $1603 for your participation.

There is no cost for you to participate in this study.
Tagged